norethindrone has been researched along with Activated Protein C Resistance in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Braat, DD; Hemelaar, M; Kenemans, P; Rosing, J; Thomassen, MC; van der Mooren, MJ | 1 |
| Eilertsen, AL; Hemker, HC; Liestøl, S; Mowinckel, MC; Sandset, PM | 1 |
| Bertina, RM; de Ronde, H; Høibraaten, E; Mowinckel, MC; Sandset, PM | 1 |
| Bannemerschult, R; Düsterberg, B; Endrikat, J; Gerlinger, C; Junge, W; Noah, M; Ruebig, A; Schmidt, W | 1 |
4 trial(s) available for norethindrone and Activated Protein C Resistance
| Article | Year |
|---|---|
Less effect of intranasal than oral hormone therapy on factors associated with venous thrombosis risk in healthy postmenopausal women.
Topics: Activated Protein C Resistance; Administration, Intranasal; Administration, Oral; Adult; Aged; Antithrombins; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Estradiol; Estrogen Replacement Therapy; Female; Hemostasis; Humans; Middle Aged; Norethindrone; Peptide Fragments; Protein S; Prothrombin; Treatment Outcome; Venous Thrombosis | 2006 |
Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system.
Topics: Activated Protein C Resistance; Administration, Oral; Blood Coagulation; Dose-Response Relationship, Drug; Drug Combinations; Estradiol; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Norethindrone; Norethindrone Acetate; Norpregnenes; Postmenopause; Protein C; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tablets; Thromboembolism; Treatment Outcome; Venous Thrombosis | 2007 |
Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial.
Topics: Activated Protein C Resistance; Aged; Double-Blind Method; Drug Combinations; Estradiol; Estrogen Replacement Therapy; Factor V; Female; Follow-Up Studies; Heterozygote; Humans; Middle Aged; Mutation; Norethindrone; Norethindrone Acetate; Recurrence; Thromboembolism | 2001 |
Impact of oral contraceptive use on APC-resistance: a prospective, randomized clinical trial with three low-dose preparations.
Topics: Activated Protein C Resistance; Adolescent; Adult; Contraceptives, Oral, Combined; Ethinyl Estradiol; Ethinyl Estradiol-Norgestrel Combination; Factor V; Female; Humans; Mutation; Norethindrone; Polymerase Chain Reaction; Prospective Studies; Protein C; Venous Thrombosis | 2001 |